We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Larazotide Acetate in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00386490
First Posted: October 11, 2006
Last Update Posted: September 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Innovate Biopharmaceuticals
  Purpose
To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.

Condition Intervention Phase
Healthy Drug: larazotide acetate Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Phase 1, randomized, double-blind, placebo controlled multi-dose study
Masking: Double (Participant, Investigator)
Masking Description:
double-blind
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of Larazotide Acetate (AT-1001) in Healthy Volunteers

Further study details as provided by Innovate Biopharmaceuticals:

Primary Outcome Measures:
  • Demonstrate the safety and tolerance of multiple, oral doses of larazotide acetate [ Time Frame: Subjects were evaluated for safety at screening, prior to administration of treatment, and following dosing of the study drug. ]
    Safety evaluations included medical history, physical examination, vital signs, clinical laboratory testing, and 12-lead electrocardiograms

  • Determine whether quantifiable concentrations of larazotide acetate are present in plasma following multiple oral doses and characterize the pharmacokinetic behavior of larazotide acetate in healthy subjects that are gluten-free and in remission [ Time Frame: Serial blood samples were collected for pharmacokinetic determinations at baseline and 2 hours post morning dose on Days 1, 2, 5, 6 and 10. ]
    Pharmacokinetic samples were taken to determine whether quantifiable concentrations of larazotide acetate were present in plasma following multiple oral doses and to characterize the pharmacokinetic behavior of larazotide acetate in celiac disease subjects.


Enrollment: 24
Actual Study Start Date: January 10, 2006
Study Completion Date: February 27, 2006
Primary Completion Date: February 27, 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Larazotide acetate 0.25 mg
larazotide acetate 0.25 mg capsule TID for 10 days
Drug: larazotide acetate
capsule for oral administration
Other Names:
  • AT-1001
  • INN-202
Experimental: Larazotide acetate 1 mg
larazotide acetate 1 mg capsule TID for 10 days
Drug: larazotide acetate
capsule for oral administration
Other Names:
  • AT-1001
  • INN-202
Experimental: Larazotide acetate 4 mg
larazotide acetate 4 mg capsule TID for 10 days
Drug: larazotide acetate
capsule for oral administration
Other Names:
  • AT-1001
  • INN-202
Experimental: Placebo
Placebo capsule TID for 10 days
Drug: larazotide acetate
capsule for oral administration
Other Names:
  • AT-1001
  • INN-202

Detailed Description:
CLIN1001-003 was a Phase 1, randomized, double-blind, placebo controlled multi-dose study to determine the safety, tolerance, and pharmacokinetics (including food effect) of 3 dose levels of larazotide acetate in healthy volunteers. Three (3) cohorts of 8 subjects, in which six (6) subjects in each cohort received larazotide acetate in escalating doses of 0.25 mg, 1 mg, or 4 mg TID for 10 days and two (2) subjects received placebo TID for 10 days, were studied. Subjects maintained a standard gluten-free diet. Subjects were dosed three times a day 30 minutes prior to meals except for the morning dosing on Days 1, 5, and 10. For the morning dosing on Days 1, 5, and 10 subjects, fasted overnight prior to dosing and for 2 hours post dose. Subjects were evaluated for safety (medical history, physical examination, vital signs, clinical laboratory testing, and 12-lead electrocardiograms) throughout the study. Serial blood samples were collected or pharmacokinetic determinations at baseline and 2 hours post morning dose on Days 1, 2, 5, 6 and 10.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female subjects
  • BMI between 18 and 30.

Exclusion Criteria:

  • Subjects with clinically significant abnormal clinical lab results
  • Hemoglobin < 12g/dL
  • Subjects with diarrhea within 3 days prior to treatment visit
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00386490


Locations
United States, Maryland
Parexel
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Innovate Biopharmaceuticals
Investigators
Study Chair: Blake Paterson, MD Alba Therapeutics
  More Information

Responsible Party: Innovate Biopharmaceuticals
ClinicalTrials.gov Identifier: NCT00386490     History of Changes
Other Study ID Numbers: CLIN1001-003
First Submitted: October 9, 2006
First Posted: October 11, 2006
Last Update Posted: September 12, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Innovate Biopharmaceuticals:
celiac disease
larazotide acetate